SCHEMBL5225488

SCHEMBL5225488

COc1ccc(C(N)=O)cc1NC(=O)c1csc(C2CCN(C(=O)c3nnc4cc(C)nn4c3C)CC2)n1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.38
SPR P35270 2/20 0.37
PPARG P37231 1/20 0.37
HPGD P15428 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.35
LMNA P02545 2/20 0.35
CYP1A2 P05177 1/20 0.35
JAK2 O60674 1/20 0.35
POLB P06746 2/20 0.34
MAPT P10636 2/20 0.34
STAT3 P40763 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KMT2A Q03164 1/20 0.34
PIM1 P11309 1/20 0.34
PIM3 Q86V86 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
CCR5 P51681 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4298330 0.83 SPR (0.45) SPRPPARGLMNAMAPT
SCHEMBL14432776 0.82 TP53 (0.47) TP53HPGDIRAK4LMNACYP1A2
SCHEMBL14433142 0.80 ALDH1A1 (0.47) TP53SPRPPARGLMNACYP1A2
SCHEMBL14432801 0.79 CYP1A2 (0.41) TP53LMNACYP1A2MAPTSTAT3
SCHEMBL6233245 0.79 SPR (0.40) TP53SPRPPARGIRAK4LMNA
SCHEMBL5229557 0.78 HPGD (0.46) TP53HPGDLMNACYP1A2MAPT
SCHEMBL14432861 0.76 TP53 (0.43) TP53SPRIRAK4LMNACYP1A2
SCHEMBL14432873 0.76 PPARG (0.41) TP53PPARGHPGDLMNACYP1A2
SCHEMBL14432488 0.76 NAMPT (0.40) HPGDIRAK4CYP1A2JAK2MAPT
SCHEMBL14432816 0.76 KDM4E (0.50) TP53HPGDLMNAPOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1581528-B1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS METRIS THERAPEUTICS LTD (GB) 2007-08-01 EP claimed
US-20060135501-A1 Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors DSPI LIMITED (GB) 2006-06-22 US claimed
EP-1581528-B1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS METRIS THERAPEUTICS LTD (GB) 2007-08-01 EP disclosed
EP-1581528-B1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS METRIS THERAPEUTICS LTD (GB) 2007-08-01 EP disclosed
US-20060135501-A1 Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors DSPI LIMITED (GB) 2006-06-22 US disclosed
EP-1581528-A1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS Metris Therapeutics Limited (GB) 2005-10-05 EP disclosed
WO-2004058751-A1 PIPERIDINYL-THIAZOLE CARBOXAMIDE DERIVATIVES FOR ALTERING VASCULAR TONE METRIS THERAPEUTICS LIMITED (GB) 2004-07-15 WO disclosed
WO-2004058750-A1 PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES AS ANGIOGENESIS INHIBITORS METRIS THERAPEUTICS LIMITED (GB) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135501-A1 Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors PGF, FLT1, VEGFA TP53 2807/4885SPR 817/4885PPARG 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.